Global Blood Therapeutics Inc
Change company Symbol lookup
Select an option...
GBT Global Blood Therapeutics Inc
FNMA Federal National Mortgage Association
FLWS 1-800-Flowers.Com Inc
EQH Axa Equitable Holdings Inc
ENTX Entera Bio Ltd
ELAN Elanco Animal Health Inc
DLX Deluxe Corp
BPMC Blueprint Medicines Corp
HZN Horizon Global Corp
RDS.A Royal Dutch Shell PLC
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Closing Price
$50.55
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
51.54
Day's Low
49.33
Volume
(Below Average)
Volume:
492,223

10-day average volume:
555,216
492,223

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.